Skip to main content
spacbrain

enGene Holdings

Closed (deSPAC)

Health Care · gene therapy biotechnology

What it is
A private company in health care preparing to list via a SPAC merger. Full profile in progress.
What it’s doing now
Merging with Forbion European Acquisition Corp. (FRBN) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.
Profile in progress — we only publish what we can verify in filings, and for this company that work isn’t finished. Identity and deal facts above are current; business detail, financials and peers will appear as the filings are parsed.

What the company says about itself

Web research — not audited

enGene is developing non-viral gene therapies for urological cancers, specifically focusing on Detalimogene for non-muscle invasive bladder cancer (NMIBC) using their proprietary DDX platform.

Markets:
Gene Therapy | Urological Cancers | Non-Viral Therapeutics
Products:
Detalimogene | DDX Platform
What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "enGene and FEAC Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company. commit $135 million USD in transaction." [https://forbion.com/news-insights/news/engene-inc-and-forbion-european-acquisition-corp-feac-nasdaq-frbn-announce-business-combination-agreement-to-create-nasdaq-listed-biotechnology-company-developing-next-generation-non-viral-locally-administered-gene-therapies/]

Source: https://engene.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

enGene Holdings is merging with Forbion European Acquisition Corp. (FRBN) currently marked Closed (deSPAC).

Headline equity value—

How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is enGene Holdings going public?

enGene Holdings has an approved merger with the SPAC Forbion European Acquisition Corp. (FRBN). Deal status: Closed (deSPAC).

Does enGene Holdings have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals